Play Video
Neurological Diagnostics Innovation
Amoneta Diagnostics seeks, develops, and qualifies innovative biomarkers for the development of diagnostics in the field of neurological diseases.
The purpose of Amoneta Diagnostics is to translate new diagnosis methods for various neurodegenerative diseases into products, and to promote the use of these tests in clinical practice.
Our know-how is based on the detection of blood biomarkers.
Currently, our biomarker R&D program is dedicated to the clinical qualification of new biomarkers and diagnostic tools for the diagnosis and the follow-up of Alzheimer’s Disease.
The purpose of Amoneta Diagnostics is to translate new diagnosis methods for various neurodegenerative diseases into products, and to promote the use of these tests in clinical practice.
Our know-how is based on the detection of blood biomarkers.
Currently, our biomarker R&D program is dedicated to the clinical qualification of new biomarkers and diagnostic tools for the diagnosis and the follow-up of Alzheimer’s Disease.
our neurodiagnostic proficiency
key figures
Empowering healthcare professionals as trusted partners, we specialize in neurodegenerative disease diagnostics, providing vital insights to aid in informed medical decision-making.
explore our products
advanced precision medicine tools aiding specialists to make personalized medical decisions, drive progress in disease characterization, and identify potential therapeutic targets.
Amoneta Diagnostics announces its participation in the forthcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases in Lisbon.
Huningue, France, December 12, 2023Together, Amoneta Diagnostics and the AD Data Initiative announce a collaboration to make data...
Amoneta Diagnostics announces that it has become a member of the Pépinière d'entreprises innovantes pH8, the region's premier business incubator focusing on healthcare and new technologies.
Get in touch
Our partners
